Domača stranIMGN • BMV
add
ImmunoGen Ord Shs
Prejšnji trg. dan.
268,50 $
Letni razpon
268,50 $ - 268,50 $
Tržna kapitalizacija
8,72 mrd. USD
Razm. P/E
-
Dividendna donosnost
-
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2023info | Sprememba L/L |
|---|---|---|
Prihodek | 113,42 mio. | 637,72 % |
Stroški poslovanja | 37,74 mio. | 12,26 % |
Čisti dohodek | 30,75 mio. | 139,54 % |
Čista dobičkovnost prihodkov | 27,11 | 105,36 % |
Earnings per share | 0,10 | 132,26 % |
EBITDA | 26,38 mio. | 134,26 % |
Efektivna davčna stopnja | −3,94 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2023info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 605,54 mio. | 95,64 % |
Skupna sredstva | 822,10 mio. | 129,13 % |
Skupne obveznosti | 260,50 mio. | 44,09 % |
Celoten lastniški kapital | 561,60 mio. | — |
Shares outstanding | 266,26 mio. | — |
Razmerje P/B | 127,25 | — |
Donosnost sredstev | 8,45 % | — |
Donosnost kapitala | 10,17 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2023info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 30,75 mio. | 139,54 % |
Denar iz dejavnosti | 2,77 mio. | 104,31 % |
Denar iz naložb | −1,35 mio. | −124,92 % |
Denar iz financiranja | 32,13 mio. | 7.056,35 % |
Neto sprememba denarnih sredstev | 33,55 mio. | 152,12 % |
Prost denarni tok | −2,32 mio. | 91,72 % |
Vizitka
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
Generalni direktor
Datum ustanovitve
1981
Sedež organizacije
Spletno mesto
Zaposleni
277
